Research

Fc Receptor Function in Normals and Systemic Lupus Erythematosus (SLE)

IRB Number: 93029

Institutional Review Board, Hospital for Special Surgery

July 06, 2005

The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.

For further information, see Understanding Clinical Trials.

Principal Investigator

Jane E. Salmon, MD

Co-Investigators

Laura Leuenberger
Nadine Spring

Summary

Rheumatologists and scientists at HSS are studying proteins (called "immune complexes") in patients with lupus. They are interested in looking at these immune complexes to try to understand how and why they cause or worsen lupus. Participating involves donating 6 tubes of blood. No extra trips to HSS are needed. We currently have over 100 patients enrolled.

Inclusion/Exclusion Criteria

Participants must have an unequivocal diagnosis of SLE (satisfying 4 or more American College of Rheumatology (ACR) criteria for SLE), APS, or both conditions. Have active disease.

Contact Information

Principal Investigator
Jane E. Salmon, MD
Email: salmonj@hss.edu

Clinical Research Coordinator
Laura Leuenberger
Tel: 212.774.2223
Email: leuenbergerl@hss.edu



Request an Appointment